Payment overview · 2025
General Payments
$172.59
9 reported records · 5 companies
Healthcare provider profile · identity verified
Matthew Nettleman
Allopathic & Osteopathic Physicians|Family Medicine · LAFAYETTE, IN · NPI 1659756484
Verified facts
What the public records show
CMS Open Payments records show Matthew Nettleman received $172.59 in general payments during 2025 across 9 reported records.
Abbott Laboratories accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $62.20 | 36.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.20 | 21.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.37 | 19.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.44 | 12.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.38 | 10.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.59 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $62.20 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 184 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
184 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1187 | 325 |
| Amlodipine Besylate | Amlodipine Besylate | 913 | 267 |
| Levothyroxine Sodium | Levothyroxine Sodium | 707 | 190 |
| Lisinopril | Lisinopril | 556 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 470 | 141 |
| Omeprazole | Omeprazole | 418 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 418 | 122 |
| Metformin Hcl | Metformin Hcl | 407 | 115 |
| Losartan Potassium | Losartan Potassium | 327 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 95 |
| Gabapentin | Gabapentin | 294 | 88 |
| Simvastatin | Simvastatin | 289 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 84 |
| Allopurinol | Allopurinol | 220 | 57 |
| Alprazolam | Alprazolam | 204 | 48 |
| Carvedilol | Carvedilol | 194 | 58 |
| Ozempic | Semaglutide | 184 | 36 |
| Furosemide | Furosemide | 183 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 39 |
| Sertraline Hcl | Sertraline Hcl | 166 | 46 |
| Eliquis | Apixaban | 162 | 34 |
| Metformin Hcl Er | Metformin Hcl | 162 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 56 |
| Potassium Chloride | Potassium Chloride | 161 | 41 |
| Meloxicam | Meloxicam | 152 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 40 |
| Buspirone Hcl | Buspirone Hcl | 138 | 34 |
| Spironolactone | Spironolactone | 138 | 39 |
| Trazodone Hcl | Trazodone Hcl | 133 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 36 |
| Ezetimibe | Ezetimibe | 118 | 35 |
| Montelukast Sodium | Montelukast Sodium | 117 | 38 |
| Alendronate Sodium | Alendronate Sodium | 106 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 105 | 78 |
| Tramadol Hcl | Tramadol Hcl | 105 | 34 |
| Indapamide | Indapamide | 101 | 29 |
| Jardiance | Empagliflozin | 101 | 25 |
| Donepezil Hcl | Donepezil Hcl | 100 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 30 |
| Valsartan | Valsartan | 84 | 27 |
| Baclofen | Baclofen | 83 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 80 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 25 |
| Finasteride | Finasteride | 79 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 22 |
| Bupropion Xl | Bupropion Hcl | 77 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 73 | 62 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 66 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 15 |
| Lorazepam | Lorazepam | 67 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 22 |
| Atenolol | Atenolol | 61 | 18 |
| Famotidine | Famotidine | 56 | 18 |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Glimepiride | Glimepiride | 52 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 13 |
| Irbesartan | Irbesartan | 48 | 13 |
| Synthroid | Levothyroxine Sodium | 48 | 15 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | 11 |
| Methylprednisolone | Methylprednisolone | 41 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 12 |
| Mirtazapine | Mirtazapine | 39 | 16 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 25 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 38 | 38 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 38 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | 12 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 21 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Prednisone | Prednisone | 31 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Linzess | Linaclotide | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 12 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Roflumilast | Roflumilast | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Griseofulvin | Griseofulvin, Microsize | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.59 · 9 records | Abbott Laboratories | Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, INTELLIS ADAPTIVESTIM, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error